DNA and Viral Vector Production Facility
Keele Science Park
Tel: +44 (0)1782 714181
About Cobra Biologics
Cobra Biologics, together with its parent company Cognate BioServices, is a leading international contract development and manufacturing organisation (CDMO) providing the highest quality development and manufacturing services for the cell and gene therapy fields, ranging from early stage development and pre-clinical services to clinical and commercial supply. Cobra and Cognate service an international customer base from its manufacturing and development facilities in the UK, Sweden, and the US.
Each of the Company's GMP approved facilities are tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for the clinical trial and the commercial markets.
As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.
Cobra, through Cognate is supported by leading shareholder EW Healthcare Partners, as well as Medivate Partners, Blackrock, and a Middle Eastern Sovereign Wealth Fund, who continue supporting the business and its expansion activities.
Microbiota, DNA Production and Fill Finish Facility
SE-864 31 Matfors
t: +46 (0)60 7858 600
Cobra Biologics Virtual Tour
49 articles with Cobra Biologics
Cobra Biologics Wins 'Company of the Year' and ‘Technical Services’ Awards in Double Success at 2017 Bionow Awards
Cobra Biologics is very proud to have been named as Company of the Year as well as being presented with the Technical Service Award in this year’s Bionow Awards.
Cobra Biologics Ltd. Embarks on £15 Million Gene Therapy Manufacturing Operations Expansion, to Create Up to 50 New Jobs
NEUWAY Pharma And Cobra Biologics Ltd. Collaborate To Develop GMP Grade Engineered Protein Capsules (EPCs) Manufacturing Process
Cobra Biologics Ltd. Appointed By University of Sheffield To Advance Novel Fusion Protein Technology Into Phase 1 Clinical Trials
Cobra Biologics Ltd. And University of Manchester Announce Collaboration To Improve Industrial Scale-Up Of Mammalian Cell Bioprocessing
Cobra Biologics Ltd. And BioCancell Therapeutics Announce Agreement To Manufacture Promising Cancer Therapy Drug
Cobra Biologics Ltd. and Novolytics Unveil Successful Development of Bacteriophages Against Bacterial Infection
Cobra Biologics Ltd. and Recopharma AB Enter Agreement to Utilise Cobra's Cell Line Development Service- MaxXpress
Cobra Biologics Ltd.' Growth is Strengthened; a New Non-Executive Director Joins Cobra's Board to Support Expansion Plans